The Effect of Intravenous Mannitol Plus Saline on the Prevention of Cisplatin-induced Nephrotoxicity: A Randomized, Double-blind, Placebo Controlled Trial

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (273 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-02-14. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 20% (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: chemotherapycisplatinpatientscancercreatinine
  Phrases that lowered it: drugsingle20comparehad received
• Accepts healthy volunteers: No (raises risk) · Who can join
• Has a data monitoring committee: not given (lowers risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports with a death: 29.4% (raises risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Phase: 2/3 (raises risk) · Design
• Maximum age: 90 (lowers risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: prevention (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 94.3% (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports before start: 3144 (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Evaluation of the Effect of Acetazolamide, Mannitol and N-acetylcysteine on Cisplatin-Induced Nephrotoxicity NCT02760901 · started 2013 · scored riskier than 15% of active trials completed
• Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma NCT01829178 · started 2013 · scored riskier than 57% of active trials completed
• Intravenous Magnesium in Patients Receiving Cisplatin NCT04481672 · started 2021 · scored riskier than 86% of active trials completed
• Comparative Study of Different Doses of Magnesium as a Protective Agent in Nephrotoxicity in Cancer Patients NCT05586009 · started 2022 · scored riskier than 7% of active trials completed
• A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function. NCT02240017 · started 2015 · scored riskier than 53% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.